Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis
Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis
批准号:
521785-2017
负责人:
Khafipour, Ehsan
金额:
$1.82万
依托单位:
依托单位国家:
加拿大
项目类别:
Engage Grants Program
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-01-01 至 2018-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic®. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Associations between Gut, Mammary and Vaginal Microbiomes in Dairy Cattle: Role in Health and Disease
-
批准号:RGPIN-2017-06535
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.84万
-
财政年份:2018
-
负责人:Khafipour, Ehsan
-
依托单位:
Enhancing gut health in dairy cows and economic and environmental sustainability of Manitoba dairy
-
批准号:490629-2015
-
项目类别:Collaborative Research and Development Grants
-
资助金额:$8.85万
-
财政年份:2017
-
负责人:Khafipour, Ehsan
-
依托单位:
Associations between Gut, Mammary and Vaginal Microbiomes in Dairy Cattle: Role in Health and Disease
-
批准号:RGPIN-2017-06535
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.84万
-
财政年份:2017
-
负责人:Khafipour, Ehsan
-
依托单位:
国内基金
海外基金
芍药苷靶向α-烯醇化酶治疗实验性自身免疫性脑脊髓炎的机制研究
-
批准号:82371809
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:聂红
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
HER2特异性双抗原表位识别诊疗一体化探针研制与临床前诊疗效能研究
-
批准号:82372014
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:魏伟军
-
依托单位: